NewAmsterdam Pharma Company's total assets for Q3 2024 were $439.19M, an increase of 5.52% from the previous quarter. NAMS total liabilities were $60.33M for the fiscal quarter, a 9.27% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.